OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

Swedish Orphan Biovitrum AB/  SE0000872095  /

Cboe Europe BXE
08/08/2024  15:20:57 Chg. - Volume Bid08/08/2024 Ask06/08/2024 Market Capitalization Dividend Y. P/E Ratio
277.30SEK - 844
Turnover: 233,440.90		 -Bid Size: - -Ask Size: - 98.65 bill.SEK - 37.27
GlobeNewswire 01/07 ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
GlobeNewswire 27/06 ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
GlobeNewswire 03/06 ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
GlobeNewswire 30/05 ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire 24/05 Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
GlobeNewswire 24/05 Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Act...
GlobeNewswire 15/05 ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at ...
GlobeNewswire 09/05 ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewswire 06/05 ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire 06/05 ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLON...
GlobeNewswire 01/05 ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on...
GlobeNewswire 04/04 ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination wit...
GlobeNewswire 03/04 ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
GlobeNewswire 01/04 Autolus Therapeutics Announces Changes to its Board of Directors
GlobeNewswire 28/03 Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
GlobeNewswire 13/03 ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business U...
GlobeNewswire 06/03 ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
GlobeNewswire 06/03 ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March...
GlobeNewswire 05/03 ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cance...
GlobeNewswire 04/01 ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
GlobeNewswire 04/01 ADC Therapeutics Provides Business Updates
GlobeNewswire 12/12/2023 ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evalua...
GlobeNewswire 07/11/2023 ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
GlobeNewswire 07/11/2023 ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
GlobeNewswire 06/11/2023 Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia